Dermata TherapeuticsDRMA
13F holders, Q2 2024 (June 30)6holders
$2.39avg. 13F price*
At the end of Q2 2024, 6 institutions reported holding Dermata Therapeutics Inc. (DRMA) in their 13F filings. The largest holders were Armistice Capital, LLC ($67K), Tower Research Capital LLC (TRC) ($4K) and UBS Group AG ($4K).
- Company
- Dermata Therapeutics Inc.
- CUSIP
- 249845405
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $78K |
| Exits | 0 | $0 |
Ownership 6 holders
| Armistice Capital, LLC | 0.00% | New | 28,000 | $67K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 1,734 | $4K |
| UBS Group AG | 0.00% | New | 1,705 | $4K |
| Acadian Asset Management LLC | 0.00% | New | 1,283 | $3K |
| Wells Fargo & Company | 0.00% | New | 45 | $108 |
| Bank of America Corp. | 0.00% | New | 3 | $7 |
"% of holder's portfolio" is DRMA's weight in each manager's 13F, not the share of Dermata Therapeutics Inc. the manager owns.